Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

Amandeep Godara, MD, Ping Zhou, MD PhD, Benjamin Rosenthal, BS, Adin Kugelmass, BSc, Denis Toskic, BS, Teresa Fogaren, NP, Cindy Varga, MD BSc, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4409.

https://doi.org/10.1182/blood-2019-126988

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Jose Acevedo, Gheorghe Doros, PhD, Raphael Szalat, John Mark Sloan, MD, Shayna Sarosiek, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 5447.

https://doi.org/10.1182/blood-2019-124980

Published: 2019

Journal Articles

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Poornima Ramadas, MBBS, Ajay Tambe, MBBS, Mijung Lee, MD

Blood (2019) 134 (Supplement_1): 5463.

https://doi.org/10.1182/blood-2019-131577

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Kaini Shen, MD, Yujun Dong, MD, Weijun Fu, Sr., MD PhD, Yu Wu, MD, Zhongxia Huang, Yongqiang Wei, PhD, Chunrui Li, MD PhD, Chunyan Sun, MD PhD, Wenrong Huang, Huihan Wang, MD PhD, Congli Zhang, Huilei Miao, Lu Zhang, MD, Xinxin Cao, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2019) 134 (Supplement_1): 1870.

https://doi.org/10.1182/blood-2019-122087

Published: 2019

Journal Articles

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Divaya Bhutani, MD, Siyang Leng, MD, Andrew Eisenberger, MD, Mathew S. Maurer, MD, Sofia Shames, MD, Jeff Goldsmith, PhD, Suzanne Lentzsch, MD PhD

Blood (2018) 132 (Supplement 1): 958.

https://doi.org/10.1182/blood-2018-99-118464

Published: 2018

Journal Articles

The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades

Andrew Staron, Lawreen H Connors, Frederick L Ruberg, John L. Berk, Lisa M Mendelson, Vaishali Sanchorawala, MD

Blood (2018) 132 (Supplement 1): 5536.

https://doi.org/10.1182/blood-2018-99-112193

Published: 2018

Journal Articles

Efficacy of Newer Combinations and Fibril-Targeting for AL Amyloidosis: A Systematic Review of Transplant and Innovative Non-Transplant Therapies

Shaunak Pandya, BS, Nadia Carenina Nunes Cavalcante Parr, MD, Muhammad Sardar, MD, Christine Chiu, Maria Serafini, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2018-99-118964

Published: 2018

Journal Articles

Neutrophil Extracellular Traps Induced By Activated Platelets Contribute to Hypercoagulable State in Patients with Colorectal Cancer

Yan Zhang, MD, Baorong Li, MD, Yingmiao Liu, MD, Cong Zhang, MD, Yan Kou, MD, Lili Zou, MD, Hui Liang, MD, Li Hou, MD, Tao Li, MD, Muxin Yu, PhD, Chunxu Wang, MD, Jingwen Du, Yueyue Li, Haijiao Jing, Jin Zhou, Jialan Shi, MD PhD

Blood (2018) 132 (Supplement 1): 1229.

https://doi.org/10.1182/blood-2018-99-110589

Published: 2018

Journal Articles

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

Jing Fu, PhD, Alan Solomon, MD, Patrick Carberry, PhD, John Castrillon, Jongho Kim, MD PhD, Suzanne Lentzsch, MD PhD, Akiva Mintz, MD PhD

Blood (2018) 132 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2018-99-118177

Published: 2018

Journal Articles

Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa

Christen L. Ebens, MD MPH, John A McGrath, MD FRCP, FMedSci, Katsuto Tamai, MD PhD, Hovnanian Alain, MD PhD, John E. Wagner, MD, Megan Riddle, Douglas R Keene, BS, Todd E. DeFor, MS, Rebecca Tryon, MS, Mei Chen, PhD, David T Woodley, MD, Kristin Hook, MD, Jakub L Tolar, MD PhD

Blood (2018) 132 (Supplement 1): 2165.

https://doi.org/10.1182/blood-2018-99-113035

Published: 2018

Journal Articles

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Anita D'Souza, MBBS, Kathryn E Flynn, PhD, Binod Dhakal, MBBS, Saurabh Chhabra, MD, Marcelo C Pasquini, MDMS, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2018-99-114783

Published: 2018

Journal Articles

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants

Cyrille Garnier, Fatma Briki, Brigitte Nedelec, Patrick Le Pogamp, Ahmet Dogan, Nathalie Rioux-Leclercq, Renan Goude, Caroline Beugnet, Laurent Martin, Marc Delpech, Frank Bridoux, Gilles Grateau, Jean Doucet, Philippe Derreumaux, Sophie Valleix

Blood (2017) 130 (25): 2799–2807.

https://doi.org/10.1182/blood-2017-07-796185

Published: 2017

Journal Articles

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Victor Jimenez-Zepeda, MD, Peter Duggan, MD FRCPC, Paola Neri, MD, Jason Tay, MD FRCPC, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 3151.

https://doi.org/10.1182/blood.V130.Suppl_1.3151.3151

Published: 2017

Journal Articles

Real-World Burden of Comorbidities in US Patients with AL Amyloidosis

Tiffany P. Quock, PhD MS, Jessie T. Yan, PhD, Eunice Chang, PhD, Spencer D Guthrie, MBA, Michael S. Broder, MD MSHS

Blood (2017) 130 (Supplement 1): 5595.

https://doi.org/10.1182/blood.V130.Suppl_1.5595.5595

Published: 2017

Journal Articles

Initial Report of a Serum Assay to Predict Amyloid Risk in Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

Emily B. Martin, PhD, Angela Williams, MS, R. Eric Heidel, PhD, Ronald H. Lands, MD, Stephen J. Kennel, PhD, Angela Dispenzieri, MD, Jonathan S. Wall, PhD

Blood (2017) 130 (Supplement 1): 5371.

https://doi.org/10.1182/blood.V130.Suppl_1.5371.5371

Published: 2017

Journal Articles

Factor VIII Binds to an Acidic Fibrinogen Variant, a Critical Component of the High-Affinity Fibrin Binding Site, Resulting in Increased Cofactor Activity

Valerie Anne Novakovic, MS, Gary E Gilbert, MD

Blood (2017) 130 (Supplement 1): 1064.

https://doi.org/10.1182/blood.V130.Suppl_1.1064.1064

Published: 2017

Journal Articles

Healthcare Utilization and Costs in Commercially Insured Patients with AL Amyloidosis

Tiffany P. Quock, PhD MS, Jessie T. Yan, PhD, Eunice Chang, PhD, Spencer D Guthrie, MBA, Michael S. Broder, MD MSHS

Blood (2017) 130 (Supplement 1): 4659.

https://doi.org/10.1182/blood.V130.Suppl_1.4659.4659

Published: 2017

Journal Articles

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Esther Imperlini, PhD, Massimiliano Gnecchi, MD PhD, Paola Rognoni, PhD, Eduard Sabidò, PhD, Maria Chiara Ciuffreda, Giovanni Palladini, MDPhD, Guadalupe Espadas, Giuseppina Palladini, Stefania Orrù, PhD, Paolo Milani, MD PhD, Stefano Perlini, MD PhD, Francesco Salvatore, MD PhD, Giampaolo Merlini, MD, Francesca Lavatelli, MD PhD

Blood (2017) 130 (Supplement 1): 4393.

https://doi.org/10.1182/blood.V130.Suppl_1.4393.4393

Published: 2017

Journal Articles

Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis

Camille Vanessa Edwards, MBBS, BSc, Julia Gould, BA, Arielle L Langer, MD MPH, Markus Y Mapara, MD PhD, Jai Radhakrishnan, MD, Mathew S. Maurer, MD, Shahzad Raza, MD, John G. Mears, MD, Siyang Leng, MD, Jonathan S. Wall, PhD, Andrew Eisenberger, MD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD

Blood (2017) 130 (Supplement 1): 509.

https://doi.org/10.1182/blood.V130.Suppl_1.509.509

Published: 2017

NARROW

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades

Efficacy of Newer Combinations and Fibril-Targeting for AL Amyloidosis: A Systematic Review of Transplant and Innovative Non-Transplant Therapies

Neutrophil Extracellular Traps Induced By Activated Platelets Contribute to Hypercoagulable State in Patients with Colorectal Cancer

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Real-World Burden of Comorbidities in US Patients with AL Amyloidosis

Initial Report of a Serum Assay to Predict Amyloid Risk in Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

Factor VIII Binds to an Acidic Fibrinogen Variant, a Critical Component of the High-Affinity Fibrin Binding Site, Resulting in Increased Cofactor Activity

Healthcare Utilization and Costs in Commercially Insured Patients with AL Amyloidosis

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only